Breakfast With the Experts: Updates in the Management of Patients With mCRPC

Join us live in San Francisco or online for an expert-led satellite symposium focused on optimizing management of metastatic castration-resistant prostate cancer. Experts will answer audience questions and discuss the latest evidence on emerging therapeutic strategies. Register now!

To Register: On the Event Dates page, click a date/time and the blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Not an official event of the 2022 ASCO Genitourinary Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer® the ASCO Foundation.


  • Welcome and Introduction
  • Overview of the Current Treatment Landscape for mCRPC
  • Investigating Approved Therapies in New Settings
  • Advances in Systemic and Targeted Therapies
  • Summary and Audience Question and Answer Session


Date / Time
Event Details


Program Director
Matthew R. Smith, MD, PhD

Claire and John Bertucci Endowed Chair in Genitourinary Cancers
Professor of Medicine,
 Harvard Medical School
Director, Genitourinary Malignancies Program
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Rana McKay, MD

Associate Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
University of California, San Diego
Genitourinary Oncology Team Lead
Moores Cancer Center
La Jolla, California

Michael Schweizer, MD

Associate Professor
Clinical Research Division
Department of Medical Oncology
University of Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with prostate cancer. 

Target Audience
This educational program is intended for medical oncologists, surgical oncologists, pathologists, and other healthcare professionals who treat patients with prostate cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Integrate novel therapies into practice to optimize the care of patients with mCRPC, considering the available evidence, and patient and disease characteristics
  • Evaluate novel therapeutically actionable molecular targets that hold promise as predictive or prognostic biomarkers for patients with mCRPC
  • Plan therapy for patients with mCRPC and bone metastases in the frontline and subsequent-line treatment settings
  • Navigate barriers to identify and enroll qualified patients with mCRPC in ongoing clinical trials actively investigating agents with novel mechanisms of action


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.